Catheter Precision (VTAK) Liabilities and Shareholders Equity (2017 - 2026)

Catheter Precision (VTAK) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $35.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 41.47% year-over-year to $35.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.0 million (down 3.41% YoY) and the FY2025 annual result came in at $15.9 million, down 42.89% from the prior year.
• Liabilities and Shareholders Equity grew to $35.1 million in Q1 2026 per VTAK's latest filing, from $15.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $48.5 million in Q1 2023 and bottomed at $15.9 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $26.5 million (2024), against an average of $27.6 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity soared 104.27%; it then tumbled 42.89% in 2025.
• Tracing VTAK's Liabilities and Shareholders Equity over 5 years: stood at $16.8 million in 2022, then jumped by 82.56% to $30.7 million in 2023, then slipped by 9.65% to $27.8 million in 2024, then tumbled by 42.89% to $15.9 million in 2025, then surged by 121.22% to $35.1 million in 2026.
• Per Business Quant, the three latest VTAK Liabilities and Shareholders Equity figures stand at $35.1 million (Q1 2026), $15.9 million (Q4 2025), and $25.5 million (Q3 2025).

Peer Comparison